Revenue and Financial Performance - Revenue increased by 13.1% to $950.725 million in 2023 compared to $840.831 million in 2022[4] - Global revenue reached $950.7 million, a year-on-year increase of 15.8%[9] - The company's global business revenue reached $950.7 million, a year-on-year increase of 15.8% (excluding exchange rate effects)[14] - Total revenue for the year ended December 31, 2023, was $950.7 million, a 13.1% increase from $840.8 million in 2022, with a 15.8% growth excluding foreign exchange impact[41] - Revenue for the year ended December 31, 2023, reached $950.7 million, representing a 15.8% growth compared to 2022 (excluding currency impact)[87] - The company achieved double-digit revenue growth in both domestic and international markets despite adverse factors[87] Gross Profit and Loss - Gross profit rose by 6.0% to $532.098 million in 2023 from $501.771 million in 2022[4] - Net loss for the year widened by 10.4% to $649.157 million in 2023 from $588.115 million in 2022[4] - Loss attributable to equity shareholders increased by 9.4% to $477.629 million in 2023 from $436.515 million in 2022[4] - Net loss was $649.1 million, with a non-Hong Kong Financial Reporting Standards adjusted net loss of $434.6 million, narrowing by 13.5%[9] - The group's non-Hong Kong Financial Reporting Standards adjusted net loss narrowed by 13.5% to $434.6 million, with a focus on achieving break-even in the coming years[15] - Net loss widened from $588.1 million in 2022 to $649.2 million in 2023, with non-HKFRS adjusted net loss improving to $434.6 million from $502.5 million[61] - The company reported a loss of $649.2 million for the year ended December 31, 2023 (attributable to equity shareholders: $477.6 million)[87] Business Segment Performance - Heart valve business revenue increased by 32.5%, large artery and peripheral vascular intervention business by 32.2%, and neurointervention business by 21.6%[9] - Surgical robot business revenue surged by 258.4%[9] - Overseas business revenue grew by 53.9% to $57.1 million[9] - Cardiovascular intervention business achieved a global revenue growth of 16.2%, with overseas revenue increasing by 71.3%[9] - Orthopedic business global revenue increased by 7.3%, with domestic revenue rising by 33.8%[10] - Rhythm management business global revenue decreased by 1.0%, but domestic revenue grew by 25.7%[10] - Revenue from the heart valve business increased by 32.5%, while the large artery and peripheral vascular intervention business grew by 32.2% year-on-year[14] - The neurointervention business achieved a revenue growth of 21.6%, with adjusted net profit increasing by 49.5%[11] - The surgical robot business revenue surged by 258.4% year-on-year, driven by core product expansion[14] - Cardiovascular business global revenue increased by 16.2% to $147.2 million, driven by international market penetration and new product contributions[16] - Overseas sales revenue for the cardiovascular business surged by 71.3% to $36.5 million, with significant growth in Asia (excluding China) and South America[17] - Domestic sales revenue for the cardiovascular business grew by 6.1% to $110.7 million, with a 66.9% increase in consumables revenue[18] - Global orthopedic revenue increased by 7.3% to $237.3 million, with domestic orthopedic revenue surging by 33.8% to $27.3 million[19] - Rhythm management business generated global revenue of $207.0 million, a 1.0% year-over-year decline (excluding currency impact)[21] - Aortic and peripheral vascular intervention business achieved revenue of $168.0 million, a 32.2% year-over-year growth (excluding currency impact), with a net profit of $69.1 million, up 31.7%[23] - Neurointervention business revenue reached $93.9 million, a year-on-year increase of 21.6% (excluding exchange rate impact), with non-Hong Kong Financial Reporting Standards adjusted net profit of $27.7 million, up 49.5% year-on-year, and net profit of $19.1 million, turning from loss to profit[25] - Heart valve business revenue reached $47.1 million, a year-on-year increase of 32.5% (excluding exchange rate impact), with gross margin improving by 3.8 percentage points[27] - Surgical robot business revenue reached $11.0 million, a significant increase of 258.4% year-over-year (excluding currency impact)[31] - Cardiovascular intervention business revenue reached $147.2 million, up 16.2% excluding foreign exchange impact, driven by market expansion and increased sales in China[42] - Orthopedic medical devices revenue was $237.3 million, a 7.3% increase excluding foreign exchange impact, with significant growth in China at 33.8%[43] - Rhythm management business revenue was $207.0 million, down 1.0% excluding foreign exchange impact, but China saw a 25.7% increase[44] - Large vessel and peripheral vascular intervention business revenue grew 32.2% excluding foreign exchange impact to $168.0 million, driven by new product launches and international expansion[45] - Neurovascular intervention business revenue increased 21.6% excluding foreign exchange impact to $93.9 million, supported by market-leading products and new approvals[46] - Heart valve business revenue rose 32.5% excluding foreign exchange impact to $47.1 million, with strong growth in both domestic and international markets[47] - Surgical robotics business revenue surged 258.4% excluding foreign exchange impact to $11.0 million, driven by commercialization of new robotic systems[48] R&D and Expenses - R&D expenses decreased by 9.6%, and management expenses decreased by 18.5%[9] - The group's R&D expenses decreased by 9.6%, while management expenses dropped by 18.5% due to organizational streamlining[15] - R&D costs decreased by 9.6% from $419.8 million in 2022 to $379.4 million in 2023, attributed to cost control and resource prioritization[54] - Distribution costs increased by 2.0% from $328.2 million in 2022 to $334.9 million in 2023, driven by market expansion and promotional activities[55] - Administrative expenses decreased by 18.5% from $247.5 million in 2022 to $201.7 million in 2023, due to effective cost control and operational efficiency improvements[56] - Other operating costs surged by 242.4% from $49.3 million in 2022 to $168.7 million in 2023, mainly due to impairment provisions for goodwill and equity-accounted investees[57] - Financing costs rose by 22.5% from $78.4 million in 2022 to $96.0 million in 2023, driven by increased interest on convertible bonds and borrowings[58] Assets and Liabilities - Total assets decreased to $3,932.405 million in 2023 from $3,994.085 million in 2022[6] - Total liabilities increased to $2,529.408 million in 2023 from $2,201.417 million in 2022[6] - Total equity decreased to $1,402.997 million in 2023 from $1,792.668 million in 2022[6] - Cash and cash equivalents decreased from $1,203.0 million in 2022 to $1,019.6 million in 2023, primarily due to increased deposits and capital expenditures[63] - Total borrowings increased by $274.9 million to $1,566.5 million in 2023, with the debt-to-asset ratio rising from 55.1% to 64.3%[64] - Capital expenditures totaled $199.1 million in 2023, allocated to building construction, equipment purchases, and R&D projects[66] International Expansion and Market Penetration - Overseas business revenue grew by 53.9% to $57.1 million[9] - The company's products are now sold in 31 overseas countries and regions, with international business revenue increasing by 51.2%[11] - Overseas sales revenue for the cardiovascular business surged by 71.3% to $36.5 million, with significant growth in Asia (excluding China) and South America[17] - Overseas sales revenue for aortic intervention products reached $11.5 million, a 51.2% year-over-year increase, with products now covering 31 countries[24] - Overseas sales revenue for the neurointervention business reached $4.5 million, a significant increase of 44.6% year-on-year, with rapid growth in the Asia-Pacific, EMEA, and Latin America regions[26] - The company plans to accelerate global expansion and integrate the MicroPort brand with global operations, aiming to bring its products to more countries and regions[37] - Non-China sales accounted for 48.2% of total revenue, driven by the company's diversified product portfolio and globalization strategy[39] Product Approvals and Certifications - The company obtained 44 NMPA Class III registrations, 19 FDA approvals, and 20 CE certifications in 2023[12] - The company's neurointervention products achieved a domestic market share of 8.2%[11] - The company and its associates obtained 33 Class III medical device registration certificates or completed significant registration changes in China, and 15 products were approved by the US FDA, with 14 receiving EU CE certification during the reporting period[34] - Castor® branched stent has been clinically applied in 16 countries globally, while Minos® abdominal aortic stent is used in 19 countries[24] - Reewarm® PTX drug balloon expanded into international markets, gaining approval in Brazil and Colombia[24] - VitaFlow Liberty® received registration approvals in Thailand, Russia, and Indonesia, with TAVI products entering nearly 100 hospitals in Argentina, Colombia, Thailand, and Russia, and achieving 120 commercial implants[28] Surgical Robotics and Innovation - Surgical robot business revenue surged by 258.4%[9] - The surgical robot business revenue surged by 258.4% year-on-year, driven by core product expansion[14] - The company's surgical robot product portfolio now covers four major sectors: endoscopy, orthopedics, panvascular, and percutaneous puncture[11] - Surgical robot business revenue reached $11.0 million, a significant increase of 258.4% year-over-year (excluding currency impact)[31] - Tuo Mai® four-arm laparoscopic surgical robot achieved multiple department approvals and secured bids in top-tier hospitals, solidifying its leading position in the domestic market[31] - Mona Lisa prostate puncture robot positioning system received NMPA approval and achieved commercialization milestones[31] - R-ONE® vascular interventional surgical robot accumulated multiple potential orders shortly after approval, demonstrating strong commercialization potential[31] - Tuo Mai® completed over 120 5G remote human clinical surgeries globally with a 100% success rate, setting multiple world records[31] - Hong Hu® orthopedic surgical robot secured 15 overseas orders and completed over 100 robot-assisted surgeries, with clinical efficacy reaching international standards[32] - Tuo Mai® achieved its first overseas sale and successfully assisted in the first overseas prostate cancer radical surgery, marking a breakthrough in international markets[32] Corporate Governance and Leadership - Dr. Chang Zhaohua, born in 1963, is the Chairman, Executive Director, and CEO of the company, with over 33 years of experience in the medical device industry[69] - Dr. Chang Zhaohua founded Shanghai MicroPort Medical Devices (Group) Co., Ltd. in 1998 and holds a Ph.D. in Biological Sciences from the State University of New York at Binghamton[69] - Bai Fuji, born in 1944, is the Honorary Chairman and Group Advisor, previously serving as Executive Director at Otsuka Medical Devices Co., Ltd. from 2011 to 2017[70] - Ashida Norihiro, born in 1954, has been a Non-Executive Director since 2006 and previously held senior positions at Mizuho Corporate Bank and Otsuka Holdings[70] - Sun Weiqin, born in 1980, was appointed as a Non-Executive Director on August 30, 2023, and currently serves as Deputy General Manager of Shanghai Zhangjiang Technology Venture Capital Co., Ltd[71] - Dr. Luo Qiyi, born in 1962, was appointed as a Non-Executive Director on August 30, 2023, with over 32 years of experience in the medical device industry and holds more than 300 patents[72] - Peng Bo, born in 1968, was appointed as a Non-Executive Director on November 10, 2023, with over 25 years of experience in marketing and sales[72] - The company is divided into three distinct regional operating units: Greater China Executive Committee, Intercontinental Orthopedics Executive Committee, and Intercontinental Rhythm Management Executive Committee, managed by the Executive Director, Founder, Chairman, and CEO Dr. Chang Zhaohua[75] - Sun Hongbin, the company's CFO and Chairman of the Greater China Executive Committee, has over 26 years of financial experience and previously served as Director and General Manager of Otsuka China from 2006 to 2010[76] - Jiang Lei, Chairman of Shanghai MicroPort Medical (Group) Co., Ltd. and Co-Chairman of the Greater China Executive Committee, has over 26 years of experience in the pharmaceutical and medical device industry and joined the company's coronary marketing department in 2006[76] - Dr. Zhang Jie, Chief Technology Officer, has led the development of the Firehawk® stent and holds 53 domestic and international patents[77] - Mr. Xu Yimin, Senior Executive Vice President, has over 24 years of experience in the medical device industry and previously served as Vice President of Quality, Registration, and Clinical Affairs[77] - Dr. Le Chengyun, Executive Vice President of Business Development and Project Management, has extensive experience in biotech and biomedical engineering, including 7 years at a biotech company in Southern California[77] - Mr. Que Yiyun, Executive Vice President of Intelligent Manufacturing and Global Supply Chain, has over 18 years of experience in the medical device industry and previously managed production and engineering at the company[77] - Ms. Hui Qing, Senior Vice President of Organizational Capability, oversees IT and medical AI functions and has over 12 years of experience at Boston Scientific[78] - Ms. He Li, Senior Vice President of Securities and Legal Affairs, has over 13 years of experience in accounting, financial analysis, and risk control, and over 14 years in corporate governance[78] - Mr. Jonathan Chen, Chief International Business Officer, has over 27 years of experience in the medical device industry and previously led transformative M&A and licensing deals at Angiotech Pharmaceuticals[79] - Mr. Todd Smith, Senior Vice President of Finance at MicroPort Orthopedics Inc., has been with the company since the acquisition of Wright Medical Technology's joint reconstruction business in 2014[79] - Mr. Yu Tianbai, Executive General Manager of Orthopedics China, has been with the company since 2015 and previously held roles at Johnson & Johnson[80] - Mr. Robert Alan Cripe, Global Commercial Officer at MicroPort Orthopedics Inc., has over 31 years of experience in the medical device industry, specializing in joint product sales and marketing[80] Shareholder and Equity Information - Otsuka Holdings Co., Ltd. holds a 20.87% stake in the company with 382,994,120 shares[112] - We'Tron Capital Limited holds an 18.69% stake in the company with 343,024,244 shares[112] - JPMorgan Chase & Co. holds a 12.61% stake in the company with 231,499,532 shares[112] - Shanghai Zhangjiang (Group) Co., Ltd. holds a 9.36% stake in the company with 171,748,050 shares[112] - Hillhouse Capital Advisors, Ltd. holds an 8.37% stake in the company with 153,694,000 shares[112] - Gaoling Fund, L.P. holds an 8.01% stake in the company with 147,009,000 shares[112] - Shanghai Zhangjiang Health Products Holdings Co., Ltd. holds an 8.97% stake in the company with 164,705,470 shares[116] - The total shares held by controlled entities and beneficial owners amount to 171,748,050 shares, representing 9.36% of the total issued shares[116] - Director and CEO Chang Zhaohua holds 49,047,671 shares, representing approximately 2.67% of the company's equity[108] - Director Luo Qiyi holds 9,802,432 shares, representing approximately 0.53% of the company's equity[108] - Director Chang Zhaohua holds 6,000,000 shares in MicroPort CardioFlow MedTech Corporation Limited, representing approximately 0.24% equity[109] - Director Luo Qiyi holds 6,413,144 shares in MicroPort CardioFlow MedTech Corporation Limited, representing approximately 0.26% equity[109] - No other directors or senior executives hold interests in the company or its associated corporations that require disclosure as of December 31, 2023[110] Financial Risks and Liquidity - The company faces financial risks, including credit risk, interest rate risk, liquidity risk, and currency risk[90] - Market risks include pressure on product pricing due to government bidding policies and uncertainties in medical insurance reimbursement levels in China[91] - The company has $448 million in convertible bonds due for redemption in June 2024 and $295.4 million in short-term interest-bearing borrowings due in 2024[189] - The company's liquidity depends on its ability to obtain external financing before June 2024 to meet the redemption requirements of convertible bondholders and to refinance existing bank borrowings[190] - The company secured a $150 million convertible term loan facility with an annual interest rate of 5.75% and an option to increase the principal by up to $50 million, totaling $200 million if fully exercised, to repay the $448 million convertible bonds due in

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 截至二零二三年十二月三十一日止年度之全年業績公告 | --- | --- | --- | --- | |------------------------------------|---------------------|--------------------------|------------------| | | | | | | 財務摘要 | | | | | | | | | | | | 截至十二月三十一日止年度 | | | | 二零二三年 千美元 | 二零二二年 千美元 | 變動百分比 | | | | | % | | 收入 | 950,725 | 840,831 | 增加 15.8% | | | | | | | | | | （剔除匯率影響） | | 毛利 | 532,098 | 501,771 | 增加 6.0% ...

Investment Rating - The report maintains a "Buy" rating for the company, citing its strong R&D capabilities and leadership in the high-value medical consumables sector [3][6] Core Views - The company's 2023 performance fell below market expectations, with a 15% YoY revenue growth (excluding currency impact) and a net loss of up to $650 million (compared to $588 million in 2022) [2] - Excluding one-time factors, the net loss was up to $436 million, representing a reduction of over 13% compared to the previous year [2] - The company remains a leader in high-value medical consumables, with significant R&D progress and a robust pipeline of innovative products [2] Financial Performance Summary - Revenue is expected to grow from $970 million in 2023E to $1,331 million in 2025E, with a CAGR of 15.3% to 15.8% [4][8] - Net loss is projected to decrease from $423 million in 2023E to $387 million in 2025E [4][8] - EPS is forecasted to improve slightly from -23.08 cents in 2023E to -21.11 cents in 2025E [4][8] Business Segment Highlights - Key business segments showed strong growth: - Cardiovascular intervention (Xinmai Medical) grew 32% YoY - Neurointervention (MicroPort NeuroTech) grew over 22% YoY - Heart valve (XinTong Medical) grew 31-36% YoY - Surgical robotics (MicroPort Robotics) grew over 350% YoY [2] - Emerging businesses contributed to exponential revenue growth [2] R&D and Product Pipeline - The company invested $170 million in R&D in H1 2023, maintaining its position as the industry leader with 30 green channel products [2] - Key product milestones include: - Vascular intervention robot, left atrial appendage occluder, and MRI-compatible pacemaker approved for market - Venous stent system, occlusion balloon, and next-generation peripheral balloon catheter submitted for approval - Second-generation absorbable stent Firesorb expected to submit for approval in Q4 2023 [2] Market Data - Current share price: HKD 6.55 [5] - Total market capitalization: HKD 12.013 billion [6] - 3-month turnover rate: 66.8% [6] Financial Statements Summary - Revenue is projected to grow steadily, reaching $1,331 million by 2025E [8] - Gross margin remains healthy, increasing from $596 million in 2023E to $832 million in 2025E [8] - Operating cash flow is expected to remain negative, with a forecast of -$337 million in 2025E [10]

智通财经APP获悉，微创医疗(00853)近期获资金加仓，2月16日暴涨24%，今日早盘再涨超13%，截至 发稿，涨13.11%，报7.59港元，成交额1.28亿港元。 国金证券指出，基于海外市场旺盛的医疗需求、充足的产品盈利空间、国内企业制造优势和技术突破逐 步成型等原因以及对外资医疗器械企业的复盘，看好未来国产医疗器械海外拓展的前景，建议关注在产 品临床创新、制造供应、客户粘性渠道布局方面具备优势的企业。 值得注意的是，心脉医疗业绩预告显示，预计2023年年度实现营业收入11.74亿元人民币到12.01亿元， 同比增加31%到34%。预计2023年年度实现归母净利润为4.75亿元到4.92亿元，同比增加33%到38%。微 创脑科学业绩预告显示，于2023年预计集团录得经调整净利润不低于1.78亿元，同比增长至少约36%； 与上年亏损2468万元相比，2023年将实现净利润扭亏为盈且增长强劲。 ...

Revenue Growth and Financial Performance - Revenue increased by 19% to $482.605 million in the first half of 2023 compared to $404.984 million in the same period of 2022[11] - Gross profit rose by 16% to $288.416 million in H1 2023 from $247.702 million in H1 2022[11] - Net loss attributable to equity shareholders decreased by 18% to $162.618 million in H1 2023 from $198.130 million in H1 2022[11] - Global business revenue increased by 25% year-over-year to $483 million, driven by strong demand recovery in the medical sector[13] - Revenue from neurovascular intervention, cardiovascular intervention, heart valve, and large vessel & peripheral vascular intervention businesses grew by 45%, 42%, 41%, and 36% respectively year-over-year[13] - Surgical robot business revenue surged by 3,110% year-over-year, driven by commercialization progress[13] - Cardiovascular intervention business international revenue increased by 94% year-over-year, supported by overseas market penetration[13] - Orthopedic business revenue grew by 10% year-over-year, with domestic joint product implant volume nearly doubling[14] - Rhythm management business revenue increased by 5% year-over-year, with domestic revenue surging 107% due to the Rega® pacemaker[14] - Large vessel & peripheral vascular intervention business international revenue rose by 114% year-over-year, covering 28 overseas countries and regions[14] - Neurovascular intervention business achieved a 505% year-over-year increase in operating profit and turned a net profit[15] - Global business revenue reached $482.6 million, a significant increase of 25% year-over-year (excluding currency impact)[19] - International (non-China) business revenue was $234.4 million, a stable increase of 11% year-over-year (excluding currency impact)[19] - Cardiovascular intervention business revenue grew by 42% year-over-year to $79.2 million (excluding currency impact)[20] - Overseas revenue for the cardiovascular business surged by 93.7% year-over-year to $16.1 million (excluding currency impact)[20] - Sales in Asia (excluding China) and South America for the cardiovascular business increased by 142% and 125% year-over-year, respectively (excluding currency impact)[20] - Revenue from coronary balloons and stents in overseas markets grew by 130% and 59% year-over-year, respectively[20] - Domestic cardiovascular intervention business achieved sales revenue of approximately $63.1 million, a significant year-on-year increase of 33.5% (excluding exchange rate effects)[21] - The company's coronary stent and balloon products maintained the top market share in China, with the volume of interventional procedures gradually recovering[21] - The company's global orthopedic business revenue reached $115.9 million, a year-on-year increase of 10.0% (excluding exchange rate effects)[22] - International (non-China) orthopedic business revenue was $104.2 million, a year-on-year increase of 7.7% (excluding exchange rate effects), with EMEA region revenue increasing by 18%[23] - China orthopedic business revenue was $11.6 million, a year-on-year increase of 51.1% (excluding exchange rate effects), driven by a surge in surgical demand[23] - The company's rhythm management business achieved global revenue of $108.3 million, a year-on-year increase of 4.7% (excluding exchange rate effects)[25] - International (non-China) rhythm management business revenue was $100.5 million, a year-on-year increase of 2.3% (excluding exchange rate effects)[25] - Bluetooth® pacemaker sales increased by 49% year-on-year, despite supply chain challenges[25] - EEMEA and Asia-Pacific regions saw significant revenue growth in rhythm management, with increases of 73% and 63% respectively (excluding exchange rate effects)[25] - The company's cardiac rhythm management business in China achieved revenue of $7.8 million, a significant increase of 50.5% year-over-year (excluding currency impact)[26] - The company's domestically developed MRI-compatible pacemaker, Rega®, drove a 107% year-over-year increase in revenue for the domestic pacemaker product portfolio[26] - The company's aortic and peripheral vascular intervention business generated revenue of $89.0 million, a 35.5% year-over-year increase (excluding currency impact), with a net profit of $39.5 million, up 30.1%[27] - The company's overseas aortic and peripheral vascular intervention business achieved sales revenue of $6.0 million, a 114.3% year-over-year increase, with products now sold in 28 countries[28] - The neurointervention business recorded revenue of approximately $42.6 million, a 45.2% year-over-year increase (excluding currency impact), with a net profit of $8.4 million, turning a profit compared to the previous year[29] - Heart valve business revenue reached $25.0 million, a significant increase of 41.4% year-over-year (excluding currency impact)[31] - Heart valve business gross margin improved by 2 percentage points to 66.1% due to cost-saving measures and economies of scale[31] - Heart valve business operating efficiency improved, with R&D, distribution, and administrative costs as a percentage of revenue decreasing by 12 percentage points[31] - Implant volume for heart valve products increased by 46% year-over-year, driven by market share gains and procedure penetration[32] - VitaFlow® and VitaFlow Liberty® products expanded to approximately 70 new hospitals, covering over 500 hospitals in total[32] - International heart valve business revenue surged by 243.1%, driven by rapid growth in Latin America[32] - Surgical robot business revenue soared by 3,110.2% year-over-year (excluding currency impact) to $4.9 million[33] - Toumai® surgical robot completed over 1,200 cases, setting a new record for domestic surgical robot procedures[33] - Honghu® surgical robot completed over 600 clinical validation cases, including high-complexity surgeries[33] - Surgical medical device business revenue reached $3.1 million, a significant increase of 39.4% year-over-year (excluding exchange rate effects)[35] - The OCT system and disposable imaging catheters in the interventional imaging field saw significant growth in shipments and market share[36] - The company's cold and hot compress therapy device achieved coverage in over 150 hospitals in China, with distribution channels covering major first- and second-tier cities[36] - The first rehabilitation robot product, the "Lower Limb Rehabilitation Trainer," entered mass production and is set to begin domestic sales[36] - La Fenice® insulin pump sales nearly doubled year-over-year, driven by expanded sales channels and improved hospital repurchase rates[37] - Total revenue for the six months ended June 30, 2023, increased by 19.2% to $482.6 million, or 24.8% excluding currency impact, compared to $405.0 million in the same period of 2022[48] - Non-China sales accounted for 48.6% of total revenue, driven by the company's global strategy and diversified product portfolio[46] - Cardiovascular intervention business revenue grew by 30.5% (42.4% excluding currency impact) to $79.2 million, driven by market expansion and product optimization in key regions[49] - Orthopedic medical devices business revenue increased by 7.6% (10.0% excluding currency impact) to $115.9 million, supported by the adoption of new technologies like surgical robots[50] - Rhythm management business revenue rose by 3.7% (4.7% excluding currency impact) to $108.3 million, driven by increased elective surgeries and new product adoption[51] - Large vessel and peripheral vascular intervention business revenue grew by 25.7% (35.5% excluding currency impact) to $89.0 million, supported by strong demand and new product launches[52] - Neurointervention business revenue increased by 36.0% (45.2% excluding currency impact) to $42.6 million, driven by market-leading products and new product penetration[53] - Heart valve business revenue rose by 31.9% (41.4% excluding currency impact) to $25.0 million, driven by increased market recognition and sales of VitaFlow® products[54] - Surgical robot business revenue surged by 3,037.8% (3,110.2% excluding currency impact) to $4.9 million, reflecting rapid market adoption[47] - Surgical robot business revenue reached $4.9 million, a 3,110.2% increase year-over-year (excluding currency impact) or 3,037.8% increase in USD terms, driven by market expansion and increased sales of core products[55] - Surgical medical device business revenue increased to $3.1 million, up 39.4% year-over-year (excluding currency impact) or 28.3% in USD terms[56] - Other business revenue rose to $14.6 million, a 92.9% increase year-over-year (excluding currency impact) or 71.3% in USD terms, driven by strong growth in emerging sectors like interventional imaging and non-vascular intervention[57] - Revenue for the six months ended June 30, 2023, was $482.605 million, an increase from $404.984 million in the same period in 2022[105] - Gross profit for the six months ended June 30, 2023, was $288.416 million, up from $247.702 million in the same period in 2022[105] - Loss from operations for the six months ended June 30, 2023, was $159.943 million, an improvement from $185.569 million in the same period in 2022[105] - Net loss attributable to equity shareholders for the six months ended June 30, 2023, was $162.618 million, compared to $198.130 million in the same period in 2022[105] - Basic loss per share for the six months ended June 30, 2023, was 8.94 cents, compared to 10.94 cents in the same period in 2022[105] - Revenue from contracts with customers for medical device sales increased to $472.745 million in the first half of 2023, up from $399.521 million in the same period in 2022[116] - Total revenue from external customers reached $482.605 million in the first half of 2023, compared to $404.984 million in the first half of 2022[116] - Revenue from the Chinese market (operating country) grew to $248.179 million in the first half of 2023, up from $188.660 million in the same period in 2022[117] - Revenue from the North American market increased to $50.354 million in the first half of 2023, compared to $48.936 million in the first half of 2022[117] - Revenue from the European market rose to $132.128 million in the first half of 2023, up from $123.806 million in the same period in 2022[117] - Revenue from the Asian market (excluding China) increased to $34.078 million in the first half of 2023, compared to $30.040 million in the first half of 2022[117] - Revenue from the South American market grew to $11.052 million in the first half of 2023, up from $6.161 million in the same period in 2022[117] - Revenue from other regions decreased to $6.814 million in the first half of 2023, down from $7.381 million in the first half of 2022[117] - Revenue from property rentals in China and the US increased to $3.259 million in the first half of 2023, up from $1.831 million in the same period in 2022[117] - The cardiovascular intervention business generated $568.128 million in revenue, while the orthopedic medical device integration business contributed $533.021 million in revenue[121] - Total revenue for the six months ended June 30, 2023, was $415.229 million, with the largest contributions from the Orthopedic Medical Devices segment at $108.674 million and the Rhythm Management segment at $104.437 million[122] - The company reported a total segment loss of $192.374 million for the six months ended June 30, 2022, with the largest losses in the Surgical Robot segment at $71.177 million and the Rhythm Management segment at $36.777 million[122] - Total segment assets as of June 30, 2022, amounted to $3.557 billion, with the Cardiovascular Intervention segment holding the highest assets at $565.823 million[122] - The company's total segment liabilities as of June 30, 2022, were $1.425 billion, with the Rhythm Management segment having the highest liabilities at $438.940 million[122] - The company's comprehensive loss for the six months ended June 30, 2023, was $219.921 million, compared to $253.275 million for the same period in 2022[123] - Government subsidies contributed $10.842 million to other net income for the six months ended June 30, 2023, compared to $6.125 million in the same period in 2022[124] - The company's financing costs for the six months ended June 30, 2023, included $8.208 million in interest on convertible bonds and $11.007 million in interest on other interest-bearing borrowings[125] - Research and development costs for the six months ended June 30, 2023, were $199.130 million, with $3.466 million capitalized as development costs[127] - The company's current tax expense for the six months ended June 30, 2023, included $10.192 million in Chinese corporate income tax and $3.723 million in taxes from other jurisdictions[128] - Certain subsidiaries of the company are eligible for a preferential corporate income tax rate of 15% due to their certification as "High-Tech Enterprises"[128] - The company's basic loss per share for the six months ended June 30, 2023, was calculated based on a loss attributable to ordinary equity shareholders of $162.618 million, compared to $198.130 million for the same period in 2022[130] - The diluted loss per share for the six months ended June 30, 2023, was $171.898 million, compared to $204.794 million for the same period in 2022[131] - The company recognized new right-of-use assets of $9.240 million for manufacturing facilities, warehouses, and office buildings in the six months ended June 30, 2023, compared to $8.802 million in the same period in 2022[132] - The company acquired property, plant, and equipment with a cost of $42.970 million in the six months ended June 30, 2023, compared to $58.613 million in the same period in 2022[132] - The company incurred building construction costs of $48.559 million and capitalized development costs of $11.796 million in the six months ended June 30, 2023, compared to $30.338 million and $8.621 million, respectively, in the same period in 2022[132] - The company disposed of or wrote off property, plant, and equipment with a net book value of $11.937 million, resulting in a loss of $5.492 million in the six months ended June 30, 2023, compared to a net book value of $612,000 and a loss of $79,000 in the same period in 2022[132] - The company's trade receivables, net of loss provisions, amounted to $188.667 million as of June 30, 2023, compared to $170.873 million as of December 31, 2022[135] - The company's trade payables amounted to $146.834 million as of June 30, 2023, compared to $143.261 million as of December 31, 2022[137] - The company received a cash consideration of RMB 58 million (equivalent to $8.027 million) for the capital increase of MicroPort YouTong Medical Technology (Jiaxing) Co., Ltd., which was recorded as "other payables" as of June 30, 2023[138] - Total interest-bearing borrowings increased to $674,664 thousand as of June 30, 2023, compared to $522,076 thousand as of December 31, 2022[140] - Bank loans with collateral amounted to $254,392 thousand, and unsecured bank loans were $420,272 thousand as of June 30, 2023[141] - The company's convertible bonds outstanding as of June 30, 2023, were $748,672 thousand, with a market value of approximately $596.8 million[143][144] - The company repurchased $35,000,000 of its 2021 convertible bonds for a total cash consideration of $31,869,000 during the first half of 2023[144] - The weighted average exercise price of outstanding share options increased to HK$17.12 as of June 30, 2023, from HK$16.16 as of December 31, 2022[149] - The company did not propose any interim or final dividends for the six months ended June 30, 2023[146] - The company did not repurchase any shares under the share reward plan during the six months ended June 30, 2023[147] - The company's total bank financing drawn as of June 30, 2023, was $109,158,000, secured by land use rights and self-use buildings with a net book value of $185,453,000[141] - The company's total bank loans secured by equity interests in subsidiaries amounted to $145,234,000 as of June 30, 2023[141] - The company is actively seeking potential financing opportunities to meet its liquidity needs[145] - The company granted 10,079,716 stock options to MicroPort CardioFlow MedTech Corporation at a weighted average exercise price of HKD 2.53, with a vesting period from March 2023 to March 2028[151] - The company granted 2,115,311 stock options to Suzhou MicroPort Orthopedics (Group) Co., Ltd. at a weighted average exercise price of CNY 11.42, with a vesting period from April 2023 to April 2028[151] - The company granted 1,803,541 shares to employees under the share incentive plan at a fair value of $4,241,000, compared to 1,578,325 shares at $3,559,000 in the same period last year[152] - MicroPort

Financial Performance - Revenue for the six months ended June 30, 2023, was $482.6 million, an increase of 25% compared to $404.98 million in the same period of 2022[2]. - Gross profit for the same period was $288.42 million, up 16% from $247.70 million year-over-year[2]. - The loss attributable to equity shareholders decreased by 18% to $162.62 million from $198.13 million in the previous year[3]. - The company reported a basic loss per share of (8.94) cents, a reduction of 18% from (10.94) cents in the prior year[4]. - Total comprehensive loss for the period was $266.95 million, compared to $372.98 million in the same period last year[5]. - The company reported a net loss of $219.921 million for the period, an improvement from a net loss of $253.275 million in the previous year[18]. - The total reported segment profit for the six months ended June 30, 2023, was a loss of $171.836 million, an improvement from a loss of $192.374 million in the same period of 2022[18]. Revenue Growth by Segment - Neurosurgery revenue grew by 45%, cardiovascular intervention revenue increased by 42%, and heart valve business revenue rose by 41% year-over-year, excluding currency effects[2]. - Revenue from the sale of medical devices was $472,745 thousand, up from $399,521 thousand, reflecting a growth of 18.3% year-over-year[12]. - The cardiovascular intervention business generated $77.751 million in revenue, while the orthopedic medical devices business generated $115.293 million, showing a year-over-year increase of 28.5% and 7.8%, respectively[16]. - The company achieved global revenue of $482.6 million, representing a significant increase of 25% year-over-year (excluding currency effects)[41]. - International (non-China) business revenue reached $234.4 million, showing a stable growth of 11% year-over-year (excluding currency effects)[41]. - The orthopedic medical device business generated global revenue of $115.9 million, reflecting a 10% year-over-year growth (excluding currency effects)[45]. - The neurointervention business recorded revenue of approximately $42.6 million, achieving a year-on-year growth of about 45.2% (excluding exchange rate effects)[51]. Cost Management and Expenses - The company effectively controlled R&D costs and administrative expenses, contributing to the reduction in losses[3]. - Research and development costs for the six months ended June 30, 2023, amounted to $199,130,000, slightly up from $195,051,000 in the same period of 2022, indicating a year-over-year increase of about 0.6%[22]. - The income tax expense for the six months ended June 30, 2023, was $13,746,000, significantly higher than $5,435,000 for the same period in 2022, reflecting an increase of approximately 153%[23]. - Administrative expenses decreased by 28.0% to $95.9 million, reflecting effective cost control and improved operational efficiency[85]. Assets and Liabilities - Non-current assets totaled $2.02 billion as of June 30, 2023, down from $2.05 billion at the end of 2022[6]. - Current liabilities included trade and other payables of $367.56 million and interest-bearing loans of $257.37 million[6]. - The company's total equity attributable to equity shareholders was $960,196 thousand as of June 30, 2023, compared to $1,135,030 thousand at the end of 2022[8]. - Non-current liabilities, including interest-bearing loans, increased to $417,298 thousand from $336,689 thousand, representing a rise of 24%[7]. - The company’s reported segment liabilities were $1.627987 billion as of June 30, 2023, compared to $1.425446 billion as of June 30, 2022, indicating an increase in liabilities[17]. Market and Strategic Developments - The company anticipates continued growth in revenue driven by market expansion and new product development initiatives[11]. - The global economic recovery remains sluggish, with manufacturing and trade investment slowing down, impacting market dynamics[40]. - The Chinese healthcare system is entering a new phase of high-quality development, with government policies aimed at enhancing healthcare service systems and resource allocation[40]. - The national health commission has announced plans to increase the number of large medical equipment configurations, which is expected to drive innovation in high-end medical equipment[40]. - The company plans to continue expanding its international market presence to enhance brand influence and provide comprehensive solutions for vascular diseases[50]. Product Development and Innovation - The company holds approximately 9,500 global patents, with products available in over 20,000 hospitals across more than 100 countries and regions[41]. - The company plans to accelerate the overseas registration and sales of core products in the second half of the year, further promoting innovative solutions for neurovascular diseases globally[52]. - The group is strategically developing specialty medical foods in 2023, expected to contribute to revenue growth[59]. - The group is actively promoting the use of surgical robots, with several products in development and registration, including the TUMAI® single-arm laparoscopic surgical robot[66]. Regulatory Approvals and Product Launches - The group has received approval for 8 products from the National Medical Products Administration (NMPA) and 2 products from the FDA during the reporting period[59]. - The new generation of DFVision® 3D electronic laparoscope received approval for domestic market launch, enhancing the company's leading position in the industry[56]. - The group has completed the submission of the FDA 510(k) application for the Evolution® hinged knee joint during the reporting period[61]. - The new generation Bluetooth pacemakers AlizeaTM and CeleaTM received FDA approval, enhancing global market coverage for high-end products[62]. Employee and Operational Insights - The group employed a total of 8,884 employees globally, with 1,890 (21.27%) located overseas as of June 30, 2023[96]. - The company aims to consolidate its leading position in the Chinese medical device market by enhancing domestic market share and leveraging its brand recognition and distribution network[97]. - Continuous improvement of existing products and active promotion of innovative product development are key strategies for the company to provide quality medical solutions[97].

Financial Performance - Revenue for the fiscal year 2022 was $840.831 million, an increase of 8.0% from $778.639 million in 2021[6]. - Gross profit for 2022 was $501.771 million, up 2.0% from $491.773 million in 2021[6]. - The company reported a net loss of $588.115 million for 2022, compared to a net loss of $351.295 million in 2021[6]. - The group recorded a net loss of $588.1 million, with a loss attributable to equity holders of $436.5 million[22]. - The group achieved a global revenue of $840.8 million, representing a significant increase of 15.6% compared to the same period last year (excluding currency effects)[22]. - The company recorded revenue of $840.8 million for the year ended December 31, 2022, representing a 15.6% increase compared to 2021, excluding currency effects[102]. - The company reported a loss of $588.1 million for the year, with a loss attributable to equity shareholders of $436.5 million[102]. Assets and Liabilities - Total assets as of 2022 were $3.994 billion, a decrease from $4.380 billion in 2021[11]. - Non-current assets increased to $2.055 billion in 2022 from $1.994 billion in 2021[11]. - Current liabilities rose to $662.125 million in 2022 from $546.757 million in 2021[11]. - The debt-to-asset ratio rose from 49.4% as of December 31, 2021, to 55.1% as of December 31, 2022[77]. - The net current asset value decreased to $1,277.1 million as of December 31, 2022, compared to $1,840.0 million as of December 31, 2021[78]. Market Reach and Growth - The company operates in over 20,000 hospitals worldwide, showcasing its extensive market reach[12]. - The company achieved a global business revenue growth of 15.6% year-on-year, reaching $840.8 million, with significant increases in various sectors: neurointervention (43.0%), aortic and peripheral (31.0%), cardiac valve (25.0%), and surgical robotics (904.8%)[17]. - International business revenue in the cardiovascular intervention sector surged by 60.0%, with EMEA and South America regions growing by 143.0% and 58.5% respectively[17]. - The orthopedic medical device sector saw a stable revenue increase of 9.5%, with international (non-China) revenue rising by 10.3%, particularly in the EMEA region, which grew by 32.6%[17]. - The company has expanded its product coverage to 22 overseas countries, with significant sales growth in the aortic and peripheral vascular intervention sector[18]. Innovation and R&D - The company holds over 8,720 patents globally, indicating a strong focus on innovation and R&D[12]. - The company is committed to becoming a world-class brand in the medical device industry, emphasizing its entrepreneurial spirit and social contributions[12]. - Research and development costs increased by 41.0% to $419.8 million, reflecting higher investments in ongoing and new R&D projects[68]. - The company is actively pursuing new product development to meet the evolving needs of the healthcare market[91]. Product Development and Approvals - A total of 22 products received approval from the National Medical Products Administration in China, with 4 products included in the special approval process for innovative medical devices[19]. - The company completed the TARGET IV NA clinical study for the Firehawk® drug-eluting stent system, which will support regulatory approvals in the U.S. and Canada[17]. - The company has established over 40 clinical application and training centers nationwide for medical robotics education and training[18]. - The company has obtained 5 EU CE certifications for key products in the aortic and peripheral vascular intervention segment, enhancing market coverage[30]. Leadership and Management - The company has a strong leadership team with diverse backgrounds in finance, technology, and business development, ensuring effective management and strategic direction[89]. - The Chief Financial Officer, Mr. Sun Hongbin, has over 25 years of financial experience, having served as Director and General Manager of Takeda China from 2006 to 2010[90]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[91]. Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[168]. - The board consists of seven members, including one executive director, three non-executive directors, and three independent non-executive directors as of December 31, 2022[171]. - The company has complied with all applicable code provisions of the corporate governance code throughout the fiscal year ending December 31, 2022, except for the separation of the roles of chairman and CEO[173]. Environmental and Social Responsibility - The company has established an Environmental, Health, and Safety (EHS) management committee to oversee its environmental protection responsibilities[103]. - The company has a strong focus on sustainable development and green operations[103]. - The company made donations amounting to approximately $8.1 million during the fiscal year ending December 31, 2022[163]. Financial Risks and Challenges - The company is exposed to various financial risks, including credit risk, interest rate risk, liquidity risk, and currency risk[105]. - Market risks include pressure on product pricing due to government policies and uncertainties in medical insurance reimbursement levels in China[106]. - The company has faced challenges due to the COVID-19 pandemic and high inflation, impacting global economic recovery[102].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 截至二零二二年十二月三十一日止年度之全年業績公告 | --- | --- | --- | --- | |----------------------|------------|--------------------------|------------------| | | | | | | 財務摘要 | | | | | | | | | | | | 截至十二月三十一日止年度 | | | | 二零二二年 | 二零二一年 | 變動百分比 | | | 千美元 | 千美元 | % | | 收入 | 840,831 | 778,639 | 15.6% | | | | | （剔除匯率影響） | | 毛利 | 501,771 | 491,773 | 2.0% | | 年內虧損 | (588,115) | (351,295) | 不適用 ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------|-------|-------|-------|--------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | ØMicroPort微创 | | | | | | | | | 罪度報告 | | | | | | | | | | | | | MicroPort Scientific Corporation 微創醫療科學有限公司 (於開曼群島註冊成立的有限公司) (股票代碼：00853) | Alley Allery Allery All All o 0 0 ti 6 150 | --- | --- | --- | --- | --- | --- | |-------|------------------------------------ ...